Related Experiment Videos
Selective microglial activation in the rat rotenone model of Parkinson's disease
Todd B Sherer1, Ranjita Betarbet, Jin Ho Kim
1Center for Neurodegenerative Disease, Emory University, 30322, Atlanta, GA, USA.
Abstract:
Chronic rotenone exposure reproduces features of Parkinson's disease (PD) (Nat. Neurosci. 3 (2000) 1301; Exp. Neurol. 179 (2003) 9). We investigated the role of glial activation in rotenone toxicity in vivo. Male Lewis rats received 2-3 mg/kg rotenone per day for up to 4 weeks. In 50% of surviving rotenone-treated animals, there was nigrostriatal dopaminergic degeneration, marked by reduced tyrosine hydroxylase immunoreactivity). Extensive microglial activation, determined by OX-42-ir, occurred in striatum and nigra of rotenone-treated animals, and was prominent before anatomical evidence of dopaminergic lesions. Microglia enlarged and developed short, stubby processes in rotenone-treated animals. Rotenone-induced microglial activation was less pronounced in cortex. Reactive astrocytosis was minimal and limited to a thin rim around the lesion. Marked microglial activation with minimal astrocytosis is another pathological feature of PD reproduced by rotenone treatment.
Insights
Chronic rotenone exposure causes Parkinson's disease (PD) features by activating microglia, a key glial cell type, before significant dopaminergic neuron loss occurs in the brain.
Area of Science:
- Neuroscience
- Toxicology
- Pathology
Background:
- Chronic rotenone exposure is a known model for Parkinson's disease (PD).
- Glial activation is implicated in neurodegenerative processes.
- The specific role of glial cells in rotenone-induced neurotoxicity requires further elucidation.
Purpose of the Study:
- To investigate the role and characteristics of glial activation in rotenone toxicity in vivo.
- To determine the temporal relationship between microglial activation and dopaminergic degeneration.
Main Methods:
- Male Lewis rats were administered 2-3 mg/kg rotenone daily for up to 4 weeks.
- Dopaminergic degeneration was assessed by tyrosine hydroxylase immunoreactivity.
- Microglial activation was quantified using OX-42 immunoreactivity.
- Astrocytosis was evaluated to assess reactive glial responses.
Main Results:
- 50% of surviving rotenone-treated rats exhibited nigrostriatal dopaminergic degeneration.
- Extensive microglial activation, characterized by cell enlargement and morphological changes, was observed in the striatum and nigra.
- Microglial activation preceded anatomical evidence of dopaminergic lesions.
- Rotenone-induced microglial activation was more pronounced than reactive astrocytosis, which was minimal.
Conclusions:
- Chronic rotenone exposure in rats reproduces key pathological features of Parkinson's disease, including dopaminergic neurodegeneration.
- Early and prominent microglial activation is a critical component of rotenone toxicity.
- The pattern of marked microglial activation with minimal astrocytosis mirrors pathological findings in human Parkinson's disease.